Drug Trial Radar · NCT01661621
Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1
Last checked: Nov 19, 2026Latest source record: Jun 25, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
395
Actual
Start
Aug 2012
Primary completion
Aug 2013
Study completion Aug 2013
Sponsor
- Lead sponsor
- Buddhist Tzu Chi General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 9, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective randomized, open label, controlled, double arm, post-marketing study to compare the treatment efficacy of first-line antimuscarinics and α-blockers monotherapy for men with moderate to severe lower urinary tract symptoms (LUTS) (International Prostate Symptom Score (IPSS-T) ≥8) and IPSS voiding-to-storage subscore ratio (IPSS-V/S) ≤1.
Conditions
- Bladder Outlet Obstruction
Interventions
Detrusitol 4 mg QDDrug
Group 1
Doxazosin 4 mg QDDrug
Group 2
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Global Response Assessment (GRA) After the Treatment DayTime frame: 1 month after initial treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Buddhist Tzu Chi General Hospital
Hualien City, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.